Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Buy
57
OMER Quote, Financials, Valuation and Earnings
Last price:
$10.29
Seasonality move
:
17.23%
Day range:
$10.08 - $12.83
52-week range:
$2.61 - $13.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.5M
Avg. volume:
1.6M
1-year change:
244.48%
Market cap:
$596.9M
Revenue:
--
EPS (TTM):
-$2.31
Analysts' Opinion
-
Consensus RatingOmeros has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Omeros has an estimated upside of 26.21% from its current price of $10.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $10.30.
Fair Value
-
According to the consensus of 2 analysts, Omeros has 26.21% upside to fair value with a price target of -- per share.
OMER vs. S&P 500
-
Over the past 5 trading days, Omeros has overperformed the S&P 500 by 37.73% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Omeros does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Omeros has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Omeros reported revenues of --.
Earnings Growth
-
Omeros has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Omeros reported earnings per share of -$0.56.
Enterprise value:
663.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-4.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$166.1M | -$164.9M | -$173.4M | -$48.2M | -$35.4M | |
| EBITDA | -$162.4M | -$149.1M | -$156M | -$43.5M | -$32.8M | |
| Diluted EPS | $3.18 | $0.32 | -$2.31 | -$0.60 | -$0.56 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $196M | $91.3M | $288.5M | $351.3M | $164.9M | |
| Total Assets | $227.1M | $123.4M | $457.6M | $493.1M | $313.3M | |
| Current Liabilities | $47.7M | $42.8M | $39.5M | $147.2M | $55.6M | |
| Total Liabilities | $314.4M | $386.1M | $503.9M | $507M | $467.5M | |
| Total Equity | -$87.3M | -$262.7M | -$46.3M | -$14M | -$154.2M | |
| Total Debt | $232.8M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$79.3M | $84.2M | -$154.6M | -$32.6M | -$32.1M | |
| Cash From Investing | $93.3M | -$197.3M | $163.5M | $57.2M | $36M | |
| Cash From Financing | $124.1M | -$1.8M | -$38M | -$483K | -$4.6M | |
| Free Cash Flow | -$79.5M | $83.8M | -$154.9M | -$32.7M | -$32.1M | |
OMER
Sector
Market Cap
$596.9M
$44.6M
Price % of 52-Week High
75.74%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
244.48%
-29.09%
Beta (5-Year)
1.973
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$8.58
200-day SMA
Buy
Level
$4.66
Bollinger Bands (100)
Buy
Level
2.89 - 8.09
Chaikin Money Flow
Sell
Level
-38.8M
20-day SMA
Sell
Level
$10.30
Relative Strength Index (RSI14)
Buy
Level
58.80
ADX Line
Buy
Level
13.78
Williams %R
Neutral
Level
-51.5625
50-day SMA
Buy
Level
$6.92
MACD (12, 26)
Buy
Level
0.48
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
77.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Stock Forecast FAQ
In the current month, OMER has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The OMER average analyst price target in the past 3 months is --.
-
Where Will Omeros Stock Be In 1 Year?
According to analysts, the consensus estimate is that Omeros share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Omeros?
Analysts are divided on their view about Omeros share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Omeros is a Sell and believe this share price will drop from its current level to --.
-
What Is Omeros's Price Target?
The price target for Omeros over the next 1-year time period is forecast to be -- according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is OMER A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Omeros is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of OMER?
You can purchase shares of Omeros via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Omeros shares.
-
What Is The Omeros Share Price Today?
Omeros was last trading at $10.29 per share. This represents the most recent stock quote for Omeros. Yesterday, Omeros closed at $10.30 per share.
-
How To Buy Omeros Stock Online?
In order to purchase Omeros stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
